Medicenna Therapeutics (TSX:MDNA) Inventories, Raw Materials & Components: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDNA Medicenna Therapeutics Corp TSX:MDNA
24 GF Score
Price C$0.37
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Inventories, Raw Materials & Components?

Medicenna Therapeutics TSX:MDNA 24 Inventories, Raw Materials & Components is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSX:MDNA with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Medicenna Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was C$0.00 Mil.

Medicenna Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Inventories, Raw Materials & Components Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medicenna Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSX:MDNA
24GF Score
Medicenna Therapeutics Corp TSX:MDNA
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of C$0.00 Mil mean?
Medicenna Therapeutics (TSX:MDNA) has a Inventories, Raw Materials & Components of C$0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Inventories, Raw Materials & Components too high?
Medicenna Therapeutics' current Inventories, Raw Materials & Components is C$0.00 Mil. Overall, Medicenna Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Inventories, Raw Materials & Components compare to VRTX and REGN?
Medicenna Therapeutics' Inventories, Raw Materials & Components of C$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Inventories, Raw Materials & Components is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (TSX:MDNA) has a current Inventories, Raw Materials & Components of C$0.00 Mil. The current Inventories, Raw Materials & Components is C$0.00 Mil. Medicenna Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Medicenna Therapeutics (TSX:MDNA), the current Inventories, Raw Materials & Components is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNAF:USA
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
24GF Score

Get the complete analysis for TSX:MDNA

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.37
Price